Korro Bio (KRRO) Stock Forecast & Price Target

Compare

550 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KRRO Analyst Ratings

Hold

1 Buy

8 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Korro

Bio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KRRO Stock 12 Month Forecast

Average Price Target

$56.60

▲(616.46% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Korro Bio in the last 3 months. The average price target is $56.60 with a high forecast of $180.00 and a low forecast of $7.00. The average price target represents a 616.46% change from the last price of $7.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","181":"$181","49.75":"$49.8","93.5":"$93.5","137.25":"$137.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,49.75,93.5,137.25,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.91,51.60923076923076,62.308461538461536,73.00769230769231,83.70692307692308,94.40615384615384,105.10538461538462,115.80461538461539,126.50384615384615,137.20307692307694,147.9023076923077,158.60153846153847,169.30076923076925,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.91,42.11692307692307,43.32384615384615,44.53076923076923,45.737692307692306,46.94461538461538,48.15153846153846,49.35846153846154,50.565384615384616,51.77230769230769,52.97923076923077,54.18615384615384,55.39307692307692,{"y":56.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.91,38.301538461538456,35.69307692307692,33.08461538461538,30.476153846153842,27.867692307692305,25.25923076923077,22.650769230769228,20.04230769230769,17.433846153846154,14.825384615384614,12.216923076923077,9.60846153846154,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.16,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$180.00

Average Price Target$56.60

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

―

Hold

―

Downgraded

11/15/25

Korro Bio (KRRO) was downgraded to a Hold Rating at William BlairWe are downgrading Korro shares from Outperform to Market Perform. On the one hand, the presence of M-AAT in AATD patients is yet another validation of viable ADAR-mediated editing in humans; on the other hand, the KRRO-110 clinical profile looks non-competitive at the moment. With Korro now switching from LNP-delivered oligos to GalNAc conjugation as it awaits further REWRITE data, we have some concerns over differentiation and the company is now well behind both Wave (WVE $6.96) and AiRNA (private) on timelines.

Catherine Novack

JonesTrading

―

Hold

―

Downgraded

11/13/25

Korro Bio's Strategic Shift Amidst Clinical Setbacks and Financial Stability Justifies Hold Rating

Steven Seedhouse

Cantor Fitzgerald

$81

Hold

925.32%

Upside

Downgraded

11/13/25

Korro Bio downgraded to Neutral from Overweight at Cantor FitzgeraldKorro Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

Ryan Deschner

Raymond James

―

Hold

―

Downgraded

11/13/25

Raymond James downgrades Korro Bio (KRRO) to a Hold

Keay Nakae

Chardan Capital

Hold

-11.39%

Downside

Downgraded

11/13/25

Analysts Offer Insights on Healthcare Companies: Abeona Therapeutics (NASDAQ: ABEO) and Korro Bio (NASDAQ: KRRO)We downgrade our rating from Buy to Neutral.

Mitchell Kapoor

H.C. Wainwright

―

Hold

―

Downgraded

11/13/25

Korro Bio (KRRO) was downgraded to a Hold Rating at H.C. Wainwright

Luca Issi

RBC Capital

$85→$8

Hold

1.27%

Upside

Downgraded

11/13/25

RBC Capital downgrades Korro Bio (KRRO) to a Hold

William Maughan

Clear Street

$93→$7

Hold

-11.39%

Downside

Downgraded

11/12/25

Korro Bio downgraded to Hold from Buy at Clear StreetKorro Bio downgraded to Hold from Buy at Clear Street

Yasmeen Rahimi

Piper Sandler

$180

Buy

2178.48%

Upside

Reiterated

10/03/25

Piper Sandler Sticks to Their Buy Rating for Korro Bio (KRRO)

Andreas Argyrides

Oppenheimer

$155

Buy

1862.03%

Upside

Initiated

01/10/25

Korro Bio initiated with an Outperform at OppenheimerKorro Bio initiated with an Outperform at Oppenheimer

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

―

Hold

―

Downgraded

11/15/25

Catherine Novack

JonesTrading

―

Hold

―

Downgraded

11/13/25

Korro Bio's Strategic Shift Amidst Clinical Setbacks and Financial Stability Justifies Hold Rating

Steven Seedhouse

Cantor Fitzgerald

$81

Hold

925.32%

Upside

Downgraded

11/13/25

Korro Bio downgraded to Neutral from Overweight at Cantor FitzgeraldKorro Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

Ryan Deschner

Raymond James

―

Hold

―

Downgraded

11/13/25

Raymond James downgrades Korro Bio (KRRO) to a Hold

Keay Nakae

Chardan Capital

Hold

-11.39%

Downside

Downgraded

11/13/25

Analysts Offer Insights on Healthcare Companies: Abeona Therapeutics (NASDAQ: ABEO) and Korro Bio (NASDAQ: KRRO)We downgrade our rating from Buy to Neutral.

Mitchell Kapoor

H.C. Wainwright

―

Hold

―

Downgraded

11/13/25

Korro Bio (KRRO) was downgraded to a Hold Rating at H.C. Wainwright

Luca Issi

RBC Capital

$85→$8

Hold

1.27%

Upside

Downgraded

11/13/25

RBC Capital downgrades Korro Bio (KRRO) to a Hold

William Maughan

Clear Street

$93→$7

Hold

-11.39%

Downside

Downgraded

11/12/25

Korro Bio downgraded to Hold from Buy at Clear StreetKorro Bio downgraded to Hold from Buy at Clear Street

Yasmeen Rahimi

Piper Sandler

$180

Buy

2178.48%

Upside

Reiterated

10/03/25

Piper Sandler Sticks to Their Buy Rating for Korro Bio (KRRO)

Andreas Argyrides

Oppenheimer

$155

Buy

1862.03%

Upside

Initiated

01/10/25

Korro Bio initiated with an Outperform at OppenheimerKorro Bio initiated with an Outperform at Oppenheimer

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Korro Bio

1 Month

xxx

Success Rate

6/15 ratings generated profit

Average Return

-0.95%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of -0.95% per trade.

3 Months

xxx

Success Rate

5/15 ratings generated profit

Average Return

-14.79%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -14.79% per trade.

1 Year

Yasmeen RahimiPiper Sandler

Success Rate

1/15 ratings generated profit

Average Return

-46.62%

reiterated a buy rating 2 months ago

Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 6.67% of your transactions generating a profit, with an average return of -46.62% per trade.

2 Years

xxx

Success Rate

0/15 ratings generated profit

Average Return

-73.52%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -73.52% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KRRO Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KRRO has received 4 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. KRRO average Analyst price target in the past 3 months is 56.60.

Each month's total comprises the sum of three months' worth of ratings.

KRRO Financial Forecast

KRRO Earnings Forecast

Next quarter’s earnings estimate for KRRO is -$2.03 with a range of -$3.19 to -$1.44. The previous quarter’s EPS was -$1.92. KRRO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year KRRO has Performed in-line its overall industry.

KRRO Sales Forecast

Next quarter’s sales forecast for KRRO is $670.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $1.09M. KRRO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year KRRO has Performed in-line its overall industry.

KRRO Stock Forecast FAQ

What is KRRO’s average 12-month price target, according to analysts?

Based on analyst ratings, Korro Bio’s 12-month average price target is 56.60.

What is KRRO’s upside potential, based on the analysts’ average price target?

Korro Bio has 616.46% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KRRO a Buy, Sell or Hold?

Korro Bio has a consensus rating of Hold which is based on 1 buy ratings, 8 hold ratings and 0 sell ratings.

What is Korro Bio’s price target?

The average price target for Korro Bio is 56.60. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $180.00 ,the lowest forecast is $7.00. The average price target represents 616.46% Increase from the current price of $7.9.

What do analysts say about Korro Bio?

Korro Bio’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of KRRO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Korro Bio (KRRO) Stock Forecast & Price Target

KRRO Analyst Ratings

KRRO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Korro Bio

KRRO Analyst Recommendation Trends

KRRO Financial Forecast

KRRO Earnings Forecast

KRRO Sales Forecast

KRRO Stock Forecast FAQ

Detailed List of Analyst Forecasts